Seda Pharmaceutical Development Services
Seda Pharmaceutical Development Services provides integrated pharmaceutical development and clinical pharmacology expertise to maximize the value of development assets. The company offers a wide range of services including consultancy, laboratory testing, modelling, and regulatory support, with a focus on complex medicines, paediatric formulations, biopharmaceutics, drug delivery systems, and complex medicines. Their mission is to support the rapid and efficient development of medicinal products through scientific rigor, innovation, and tailored solutions.
Industries
Nr. of Employees
small (1-50)
Seda Pharmaceutical Development Services
Services
Scientific consultancy across pharmaceutical development, DMPK, clinical pharmacology and CMC regulatory strategy, including regulatory authoring and project oversight.
On-site laboratory capabilities for screening, formulation testing, analytical method development, dissolution method development (including CRDS) and nanomedicine characterisation to support preclinical and clinical development.
Integration of preclinical and clinical data using mechanistic and empirical models (absorption, PBPK, population PK/PKPD, translational PKPD and QSP) to inform dose selection, trial design and formulation strategy.
Clinical-scale GMP manufacturing and testing capability for investigational medicinal product supply, with project management and technical oversight of clinical supply chains.
Specialist support for development, characterisation and regulatory planning for nanomedicines, lipid nanoparticles, long-acting parenteral systems and other complex drug delivery platforms.
Scientific consultancy across pharmaceutical development, DMPK, clinical pharmacology and CMC regulatory strategy, including regulatory authoring and project oversight.
On-site laboratory capabilities for screening, formulation testing, analytical method development, dissolution method development (including CRDS) and nanomedicine characterisation to support preclinical and clinical development.
Integration of preclinical and clinical data using mechanistic and empirical models (absorption, PBPK, population PK/PKPD, translational PKPD and QSP) to inform dose selection, trial design and formulation strategy.
Clinical-scale GMP manufacturing and testing capability for investigational medicinal product supply, with project management and technical oversight of clinical supply chains.
Specialist support for development, characterisation and regulatory planning for nanomedicines, lipid nanoparticles, long-acting parenteral systems and other complex drug delivery platforms.
Expertise Areas
- Oral drug delivery and biopharmaceutics
- DMPK and human dose prediction
- PK/PKPD and PBPK modelling
- Complex medicines and nanomedicine development
Key Technologies
- Physiologically based pharmacokinetic (PBPK) modelling
- Population PK / PKPD modelling
- In silico absorption modelling
- Non-compartmental analysis (NCA)
News & Updates
Prof. Paul Stott, CEO of Seda, chaired the Pharmaceutical Development panel at the virtual Bionow Oncology conference, focusing on drug delivery in cancer therapeutics.
Seda was awarded the Bionow Investment Deal of the Year 2024, recognizing its growth and innovation in pharmaceutical development.
Seda’s new GMP manufacturing facility was officially opened by Andy Burnham, enhancing its clinical manufacturing capabilities.
Seda introduced its new Clinical Manufacturing Services division to support clinical trial material production.
A case study highlighting Seda’s formulation development for preclinical studies at The Institute of Cancer Research.
Research using advanced imaging and molecular modelling techniques revealed how individual crystals interact within powders, informing drug product development.
Prof. Paul Stott, CEO of Seda, chaired the Pharmaceutical Development panel at the virtual Bionow Oncology conference, focusing on drug delivery in cancer therapeutics.
Seda was awarded the Bionow Investment Deal of the Year 2024, recognizing its growth and innovation in pharmaceutical development.
Seda’s new GMP manufacturing facility was officially opened by Andy Burnham, enhancing its clinical manufacturing capabilities.
Seda introduced its new Clinical Manufacturing Services division to support clinical trial material production.
A case study highlighting Seda’s formulation development for preclinical studies at The Institute of Cancer Research.
Research using advanced imaging and molecular modelling techniques revealed how individual crystals interact within powders, informing drug product development.